CVS Health Corporation (CVS)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?
CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.
Here's Why CVS Health (CVS) is Poised for a Turnaround After Losing 7.7% in 4 Weeks
CVS Health (CVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CVS Health Has Become A Strong GARP Pick (Rating Upgrade)
This article upgrades my rating on CVS Health to 'Buy' as recent negative industry headlines have pressured its valuation. These negatives are fully priced in already, creating a strong GARP (growth at a reasonable price) opportunity. Despite margin pressures, robust EPS growth is projected at double-digit rates. Yet, the forward P/E is just 10x.
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
CVS Health - Q2 Earnings Are A Referendum On Future Of Company
CVS has transformed from a retail pharmacy to a complex healthcare conglomerate, but its stock price has remained stagnant over the past decade. The Medicare Advantage business, once seen as a growth engine, has become less profitable, leading to management shakeups and activist investor intervention. Despite a short-term recovery in 2025, CVS faces ongoing challenges: declining retail, regulatory threats to PBM, and uncertain Medicare Advantage profitability.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.
Here's Why CVS Health (CVS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
